Dr. Sanchari Sinha Dutta

Feature Writer

B.Sc. Physiology, M.Sc. Physiology, Ph.D. Physiology

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world.

Since she was very young, Dr. Dutta was passionate about the world of science and making it accessible to all. During her time at school, Dr. Dutta particularly enjoyed taking part in biology experiments in the laboratory. The inner workings and diversity of the human body used to surprise her every day and eventually inspired her to become a biologist.

In order to learn more about the subject, Sanchari decided to take biology as her main subject at university and gained Bachelor of Science (B.Sc.) and Master of Science (M.Sc.) degrees in human physiology from the University of Calcutta, India.

This was followed by a Ph.D., also in physiology. During her tenure (2004 – 2010), she received the ‘Surg. Rear Admiral M.S. Malhotra Research Prize’ for best publication from the Defence Institute of Physiology and Allied Sciences, India.

Her thirst for knowledge and dream to be a science writer were always abreast throughout her academic tenure. However, instead of starting her career as a writer straight away, Sanchari decided to further her knowledge of the molecular biology of the human body and carried out postdoctoral research for 6 years after her Ph.D.

During this period, Dr. Dutta received ‘Dean of Faculty fellowship of Weizmann Institute of Science, Israel’ and ‘PBC fellowship for outstanding post-doctoral researchers from China and India in Israeli universities’.

Alongside bench work, she authored more than 10 original research articles, all published in renowned international journals.

In 2016, she started working with a leading medical communication company and formally became a freelance science writer. Since then, she has engaged in writing a wide variety of scientific articles, including original research articles, review articles, science discoveries, popular science articles, and healthcare articles. Her first review article as a science writer was recently published in the journal ‘Oxidative Medicine and Cellular Longevity’.

Her work with News Medical offers a great platform for a wide range of audience to learn about the science behind good health.

See less

Articles from Sanchari Sinha Dutta

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Can memory T cell responses to seasonal coronaviruses protect against severe COVID-19?

In a recent study published in the journal Science Immunology, scientists have revealed that the presence of CD8+ T cells against conserved epitopes of seasonal coronaviruses is associated with mild coronavirus disease 2019 (COVID-19). These immune cells exhibit a memory phenotype and provide protection against severe disease.

7 Jul 2021

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

A team of US-based scientists recently demonstrated that pro-thrombotic autoantibodies that target angiotensin II type 1 receptor (AT1R) may be associated with endothelial complications observed in coronavirus disease 2019 (COVID-19), a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Scientists identify breakthrough cases of SARS-CoV-2’s delta variant in fully vaccinated individuals

In a recent study conducted at the Baylor College of Medicine, Houston, USA, scientists have identified six vaccine breakthrough cases caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

The antibodies are capable of neutralizing a wide range of SARS-CoV-2 variants even at sub-nanomolar concentrations. In addition, the combinations of these antibodies reduce the risk of generating escape mutants in vitro. The study is published in the journal Science.

5 Jul 2021

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

The findings reveal that the two-dose regimen of the vaccine is almost 90% effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, the vaccine shows high efficacy against the B.1.1.7 variant (Alpha) of SARS-CoV-2.

5 Jul 2021

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

In a recently published article scientists have provided a detailed description of the utility of mannose-specific lectins in preventing coronavirus infections. They have specifically explained how mannose-specific lectins derived from plants, algae, fungi, and bacteria selectively bind N-glycans present on the surface of viral spike protein and how such interactions can be medically utilized to control coronavirus transmission.

1 Jul 2021

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

A team of US-based scientists recently developed a novel vaccine candidate against SARS-CoV-2, the causative pathogen of COVID-19. The vaccine is composed of extracellular vesicles of Salmonella typhimurium incorporated with the spike receptor-binding domain (RBD) of SARS-CoV-2. Upon intranasal administration in hamsters, the vaccine induces strong blood antibody titers and protects against severe COVID-19.

30 Jun 2021

Could the activation of FcγRIII/CD16 by anti-spike SARS-CoV-2 antibodies independently determine COVID-19 severity?

A team of scientists from Germany recently investigated whether hyperactivation of immune receptors that recognize the Fc part of an IgG molecule (FcγR) can lead to immunopathologic changes in coronavirus disease 2019 (COVID-19) patients. They have observed that hyperactivation of FcγRIII (CD16) by proinflammatory IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can significantly contribute to COVID-19 related immunopathology.

28 Jun 2021

Dr. Sanchari Sinha Dutta

Articles from Sanchari Sinha Dutta

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Can memory T cell responses to seasonal coronaviruses protect against severe COVID-19?

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

Scientists identify breakthrough cases of SARS-CoV-2’s delta variant in fully vaccinated individuals

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

Could the activation of FcγRIII/CD16 by anti-spike SARS-CoV-2 antibodies independently determine COVID-19 severity?

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News